论文部分内容阅读
目的:旨在观察思密达治疗小儿腹泻的临床疗效,以期为临床应用提供依据。方法:本研究收集了2012年3月至2015年3月期间,来我院治疗的小儿腹泻患者80例,将其按照随机对照原则分为观察组和对照组各40例。两组患者均采用金双歧治疗,观察组在此基础上加用思密达治疗治疗。连续治疗7天后,将两组患儿的临床疗效、症状改善情况、不良反应进行对比,分析其异同。结果:经过治疗后,观察组患儿的临床疗效明显优于对照组,大便好转、腹痛消失、止泻、退热所需的时间亦明显低于对照组,差异有统计学意义(P<0.05);同时,两组患儿均无明显的不良反应,差异无统计学意义(p>0.05)。结论:临床治疗小儿腹泻时,在口服金双歧的基础上加用思密达治疗,临床疗效确切,可以有效改善临床症状,缩短症状改善所需时间,且无明显不良反应,值得在临床上推广使用。
Objective: To observe the clinical efficacy of Smecta in the treatment of children with diarrhea, with a view to provide the basis for clinical application. Methods: This study collected from March 2012 to March 2015, 80 cases of pediatric diarrhea treated in our hospital, according to the principle of randomized control were divided into observation group and control group of 40 cases. Two groups of patients were treated with bifidobacterium, the observation group on the basis of this treatment with Smectite treatment. After 7 days of continuous treatment, the clinical efficacy, symptom improvement and adverse reactions of the two groups were compared and the similarities and differences were analyzed. Results: After treatment, the clinical efficacy of the observation group was significantly better than that of the control group, stool improved, abdominal pain disappeared, antidiarrheal and antipyretic time is also significantly lower than the control group, the difference was statistically significant (P <0.05 At the same time, there was no significant adverse reactions in both groups, the difference was not statistically significant (p> 0.05). Conclusion: Clinical treatment of children with diarrhea, oral administration of Bifidobacterium on the basis of the addition of Smectite treatment, the exact clinical efficacy, can effectively improve the clinical symptoms, shorten the time required for symptom improvement, and no significant adverse reactions, it is worth to promote the use of the clinical .